SEC Tracker
Get the app

Vir Biotechnology VIR

Vir Biotechnology partners with Gilead

Form
8-K
Filed
Importance
Routine
  1. Collaboration to develop 3 PRO-XTEN TCE candidates for solid tumors
  2. $25M equity investment from Gilead at 30% premium
  3. Potential $1.74B in milestones and royalties
  4. Exclusive license for Gilead to develop and commercialize TCEs

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Vir Biotechnology files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. ImmunityBio IBRX public float $690M, Jun 30, 2025
  2. Anavex Life Sciences AVXL public float $708M, Mar 31, 2025, over 18 months old
  3. Immunome IMNM public float $729M, Jun 30, 2025
  4. Anaptysbio ANAB public float $633M, Dec 31, 2025
  5. Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.